Sanofi pays $180m for rights to Kali autoimmune drug
California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in near-term payments for rights to a T-cell engager (TCE) for autoimmune diseases. The agreement gives the French pharma group …